Vaderis Raises $152M to Lead Phase 3 Study in Rare Blood Vessel Disorder HHT

Vaderis Therapeutics secured an oversubscribed $152 million Series B financing to fund a Phase 3 trial of its AKT inhibitor, engasertib (VAD044), for hereditary hemorrhagic telangiectasia (HHT), a rare blood vessel disorder.

There are currently no approved therapies specifically for HHT, which affects about 1 in 3,800 people and causes severe nosebleeds, anemia, and vascular abnormalities.

The global Phase 3 HEROIC trial is a once-daily oral study in moderate-to-severe HHT patients, with results expected around 2028, and existing data show significant reductions in bleeding duration and frequency.

The round was co-led by Life Sciences at Goldman Sachs Alternatives and TCGX, with Omega Funds, EQT Life Sciences, Perceptive Advisors, and Kalehua Capital joining prior investors Medicxi and Droia.